This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: TransMedics Group (TMDX), Erasca (ERAS) and Incyte (INCY)

Tipranks - Tipranks - Wed Jun 10, 5:48AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on TransMedics Group (TMDX), Erasca (ERAS) and Incyte (INCY).

Introducing TipRanks MCP for Agents

TransMedics Group (TMDX)

Needham analyst Michael Matson maintained a Buy rating on TransMedics Group today and set a price target of $142.00. The company’s shares closed last Monday at $71.14, close to its 52-week low of $55.00.

According to TipRanks.com, Matson is a 3-star analyst with an average return of 1.1% and a 44.4% success rate. Matson covers the Healthcare sector, focusing on stocks such as Insight Molecular Diagnostics, Establishment Labs Holdings, and Zimmer Biomet Holdings. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TransMedics Group with a $119.63 average price target, a 72.9% upside from current levels. In a report issued on June 5, William Blair also maintained a Buy rating on the stock.

See the top stocks recommended by analysts >>

Erasca (ERAS)

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Hold rating on Erasca, with a price target of $16.00. The company’s shares closed last Monday at $12.87.

According to TipRanks.com, Stranahan is a 4-star analyst with an average return of 3.9% and a 45.4% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Perspective Therapeutics, and Crispr Therapeutics AG. ;'>

Currently, the analyst consensus on Erasca is a Strong Buy with an average price target of $21.00, which is a 67.6% upside from current levels. In a report issued on May 28, TipRanks – PerPlexity also reiterated a Hold rating on the stock with a $12.00 price target.

Incyte (INCY)

In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Hold rating on Incyte, with a price target of $103.00. The company’s shares closed last Monday at $100.64.

According to TipRanks.com, Frommer is a 1-star analyst with an average return of -1.4% and a 50.4% success rate. Frommer covers the Healthcare sector, focusing on stocks such as Lakefront Biotherapeutics, 4D Molecular Therapeutics, and Bicara Therapeutics Inc. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Incyte with a $110.06 average price target, implying a 7.1% upside from current levels. In a report released yesterday, William Blair also maintained a Hold rating on the stock.

Read More on TMDX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).